- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2334
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Vaccine-associated measles in a patient treated with natalizumab: a case report ; volume:20 ; number:1 ; day:14 ; month:10 ; year:2020 ; pages:1-4 ; date:12.2020
BMC infectious diseases ; 20, Heft 1 (14.10.2020), 1-4, 12.2020
- Creator
-
Miauton, Alix
Tan, Rainer
Pantazou, Vasiliki
Du Pasquier, Renaud
Genton, Blaise
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12879-020-05475-9
- URN
-
urn:nbn:de:101:1-2020112913303291582469
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Miauton, Alix
- Tan, Rainer
- Pantazou, Vasiliki
- Du Pasquier, Renaud
- Genton, Blaise
- SpringerLink (Online service)
Other Objects (12)
Local public health response to vaccine-associated measles: case report
Necrotizing fasciitis following measles vaccine administration: a case report
Resurgence of Measles in Europe: A Systematic Review on Parental Attitudes and Beliefs of Measles Vaccine
Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists
Measles-Associated CNS Complications: A Review
COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
Analysis of primary resistance phenomena to oncolytic measles vaccine virus
Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus
Ein Peptidkonjugatvakzin gegen Masern : = A peptide-conjugate vaccine against measles
Measles virus as vaccine platform against highly pathogenic emerging viruses
Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus
Is early measles vaccination associated with stronger survival benefits than later measles vaccination?
Local public health response to vaccine-associated measles: case report
Necrotizing fasciitis following measles vaccine administration: a case report
Resurgence of Measles in Europe: A Systematic Review on Parental Attitudes and Beliefs of Measles Vaccine
Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists
Measles-Associated CNS Complications: A Review
COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
Analysis of primary resistance phenomena to oncolytic measles vaccine virus
Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus
Ein Peptidkonjugatvakzin gegen Masern : = A peptide-conjugate vaccine against measles
Measles virus as vaccine platform against highly pathogenic emerging viruses
Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus
Is early measles vaccination associated with stronger survival benefits than later measles vaccination?
Local public health response to vaccine-associated measles: case report
Necrotizing fasciitis following measles vaccine administration: a case report
Resurgence of Measles in Europe: A Systematic Review on Parental Attitudes and Beliefs of Measles Vaccine
Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists
Measles-Associated CNS Complications: A Review
COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
Analysis of primary resistance phenomena to oncolytic measles vaccine virus
Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus
Ein Peptidkonjugatvakzin gegen Masern : = A peptide-conjugate vaccine against measles
Measles virus as vaccine platform against highly pathogenic emerging viruses
Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus